Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 15, 2003, Pages 20-25

  Takimoto, Chris H ^a   Remick, Scot C ^b   Sharma, Sunil ^b   Mani, Sridhar ^b   Ramanathan, Ramesh K ^b   Doroshow, James H ^b   Hamilton, Anne ^b   Mulkerin, Daniel ^b   Graham, Martin ^b   Lockwood, Graham F ^b   Ivy, Percy ^b   Egorin, Merrill ^b   Greenslade, Denis ^b   Goetz, Andrew ^b   Grem, Jean L ^b  

^a CTRC Institute for Drug Development   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; PLATINUM;

ABDOMINAL PAIN; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG PROTEIN BINDING; DYSESTHESIA; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; INJECTION SITE; INJECTION SITE IRRITATION; KIDNEY DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN IRRITATION; SOLID TUMOR; THROMBOCYTOPENIA; ULTRAFILTRATION; URINARY EXCRETION; VOMITING;

EID: 0141993875     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00401-9     Document Type: Conference Paper

References (22)

1. Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976, 1993
2. Silvestro L, Anal H, Sommer F, et al: Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum; L-OHP) with CDDP on various cells: Correlation with intracellular accumulation. Anticancer Res 10: 1376, 1990 (abstr)
3. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
4. Fukuda M, Ohe Y, Kanzawa F, et al: Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 15:393-398, 1995
5. Dunn TA, Schmoll H, Grunwald V, et al: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 15:109-114, 1997
6. Woynarowski JM, Chapman WG, Napier C, et al: Sequence and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770-777, 1998
7. Schmidt W, Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805, 1993
8. Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886, 1996
9. Chau I, Webb A, Cunningham D, et al: An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 115:786-792, 2001
10. Chollet P, Bensmaine MA, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070, 1996
11. Dieras V, Bougnoux P, Petit T, et al: Multicentre phase II study of oxaliplatin as a single-gent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann Oncol 13:258-266, 2002
12. Monnet I, Brienza S, Hugret F, et al: Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 34:1124-1127, 1998
13. Misset JL: Oxaliplatin in practice. Br J Cancer 77:4-7, 1998 (suppl 4)
14. Mani S, Graham MA, Bregman DB, et al: Oxaliplatin: A review of evolving concepts. Cancer Invest 20:246-263, 2002
15. Beauchemin D: Inductively coupled plasma mass spectrometry. Anal Chem 74:2873-2893, 2002
16. Graham MA, Lockwood GF, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218, 2000
17. Gamelin E, Bouil AL, Boisdron-Celle M, et al: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 3:891-899, 1997
18. Massari C, Brienza S, Rotarski M, et al: Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157-164, 2000
19. Doroshow JH, Synold T, Longmate J, et al: Phase I pharmacokinetic (PK) trial of oxaliplatin (OX) in solid tumor patients (pts) with varying degrees of liver dysfunction (LD). Proc Am Soc Clin Oncol 20:113a, 2001 (abstr 449)
20. Takimoto CH, Remick SC, Sharma S, et al: Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 21:2664-2672, 2003
21. Allain P, Heudi O, Cailleux A, et al: Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 28:1379-1384, 2000
22. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989